NewLink Genetics Corporation (NASDAQ:NLNK) marched up 33.73% compared to a 52-week low price of $5.90. The shares were last seen trading -5.73% lower, taking the closing price at $7.89 on 12/06/2017. At recent session, the prices were hovering between $7.8 and $8.375. This company shares are 193.66% off its target price of $23.17 and the current market capitalization stands at $285.07M. The recent change has given its price a -17.51% deficit over SMA 50 and -68.65% deficit over its 52-week high. The stock witnessed -12.14% declines, -41.99% declines and 26.44% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found NLNK’s volatility during a week at 6.98% and during a month it has been found around 6.55%.NewLink Genetics Corporation (NLNK) Top Holders
Institutional investors currently hold around $164 million or 56.6% in NLNK stock. Look at its top three institutional owners. First Eagle Investment Management, Llc owns $20.88 million in NewLink Genetics Corporation, which represents roughly 7.32% of the company’s market cap and approximately 12.73% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 1,906,014 shares of the stock are valued at $15.95 million. The third largest holder is Millennium Management Llc, which currently holds $10.87 million worth of this stock and that ownership represents nearly 3.81% of its market capitalization.NewLink Genetics Corporation 13F Filings
At the end of 09/30/2017 reporting period, 64 institutional holders increased their position in NewLink Genetics Corporation (NASDAQ:NLNK) by some 7,551,846 shares, 57 decreased positions by 4,131,359 and 24 held positions by 7,952,242. That puts total institutional holdings at 19,635,447 shares, according to SEC filings. The stock grabbed 32 new institutional investments totaling 3,431,438 shares while 15 institutional investors sold out their entire positions totaling 2,126,415 shares.NewLink Genetics Corporation (NASDAQ:NLNK) Insider Trades
Multiple company employees have indulged in significant insider trading. NewLink Genetics Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Principal Accounting Officer Langren Carl W. has sold 2,229 shares of NewLink Genetics Corporation (NLNK) in trading session dated Nov. 21, 2017. These shares are worth $20,172 and were traded at $9.05 each. The SEC filing shows that Stine Seed Farm, Inc. performed a purchase of 780,487 shares. The 10% Owner added these shares by way of transaction on Oct. 06, 2017. The company’s shares were assimilated at $10.25 per share worth to an investment of some $7,999,992 on account of Stine Seed Farm, Inc..
Principal Accounting Officer, Langren Carl W., sold 3,943 common shares of NewLink Genetics Corporation (NLNK) in the open market. In a transaction dated Dec. 14, 2016, the shares were put up for sale at an average price of $10.85, raking in a sum of $42,782. After this sale, 60,382 common shares of NLNK are directly owned by the insider, with total stake valued at $476,414.
In the transaction dated Jun. 06, 2016, the great number of shares acquired came courtesy the Director; Talarico Ernest Iii added a total of 4,065 shares at an average price of $12.32, amounting to approximately $50,081. The insider now directly owns 36,328 shares worth $286,628.NewLink Genetics Corporation (NLNK) Analyst Guide
Several analysts have released their opinion on NewLink Genetics Corporation (NASDAQ:NLNK), with 6 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1 average brokerage recommendation.